Vir Biotechnology Inc. (VIR) Tops Q1 EPS by 57c

Vir Biotechnology Inc. (NASDAQ: VIR) reported Q1 EPS of ($0.48), $0.57 better than the analyst estimate of ($1.05). Revenue for the quarter came in at $56.38 million versus the consensus estimate of $11.99 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance